Intrinsic value of Abeona Therapeutics - ABEO

Previous Close

$8.05

  Intrinsic Value

$0.83

stock screener

  Rating & Target

str. sell

-90%

Previous close

$8.05

 
Intrinsic value

$0.83

 
Up/down potential

-90%

 
Rating

str. sell

We calculate the intrinsic value of ABEO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  1
  2
  3
  4
  6
  9
  12
  15
  20
  25
  31
  38
  46
  54
  64
  74
  86
  98
  111
  124
  139
  154
  170
  187
  205
  223
  242
  262
  283
  304
Variable operating expenses, $m
  35
  53
  77
  110
  153
  210
  280
  367
  471
  593
  732
  896
  1,079
  1,284
  1,510
  1,757
  2,023
  2,310
  2,616
  2,942
  3,285
  3,647
  4,027
  4,425
  4,840
  5,273
  5,725
  6,194
  6,682
  7,189
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  35
  53
  77
  110
  153
  210
  280
  367
  471
  593
  732
  896
  1,079
  1,284
  1,510
  1,757
  2,023
  2,310
  2,616
  2,942
  3,285
  3,647
  4,027
  4,425
  4,840
  5,273
  5,725
  6,194
  6,682
  7,189
Operating income, $m
  -34
  -51
  -74
  -105
  -147
  -201
  -268
  -351
  -451
  -569
  -701
  -858
  -1,034
  -1,230
  -1,446
  -1,682
  -1,938
  -2,212
  -2,506
  -2,817
  -3,146
  -3,493
  -3,857
  -4,238
  -4,636
  -5,050
  -5,482
  -5,932
  -6,399
  -6,885
EBITDA, $m
  -29
  -45
  -68
  -99
  -139
  -191
  -257
  -337
  -434
  -548
  -680
  -832
  -1,003
  -1,193
  -1,403
  -1,632
  -1,880
  -2,146
  -2,431
  -2,733
  -3,052
  -3,388
  -3,741
  -4,111
  -4,497
  -4,899
  -5,318
  -5,754
  -6,207
  -6,679
Interest expense (income), $m
  0
  0
  0
  1
  1
  2
  3
  4
  5
  7
  9
  11
  14
  18
  21
  26
  30
  35
  40
  46
  52
  59
  66
  73
  81
  89
  97
  106
  115
  125
  135
Earnings before tax, $m
  -34
  -51
  -74
  -106
  -149
  -203
  -272
  -356
  -458
  -578
  -713
  -872
  -1,051
  -1,251
  -1,472
  -1,712
  -1,973
  -2,253
  -2,552
  -2,870
  -3,205
  -3,559
  -3,930
  -4,319
  -4,725
  -5,148
  -5,589
  -6,047
  -6,524
  -7,020
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -34
  -51
  -74
  -106
  -149
  -203
  -272
  -356
  -458
  -578
  -713
  -872
  -1,051
  -1,251
  -1,472
  -1,712
  -1,973
  -2,253
  -2,552
  -2,870
  -3,205
  -3,559
  -3,930
  -4,319
  -4,725
  -5,148
  -5,589
  -6,047
  -6,524
  -7,020

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  64
  99
  147
  214
  302
  415
  557
  731
  940
  1,188
  1,475
  1,803
  2,174
  2,586
  3,041
  3,537
  4,075
  4,652
  5,269
  5,924
  6,616
  7,345
  8,110
  8,911
  9,748
  10,620
  11,528
  12,473
  13,456
  14,477
Adjusted assets (=assets-cash), $m
  64
  99
  147
  214
  302
  415
  557
  731
  940
  1,188
  1,475
  1,803
  2,174
  2,586
  3,041
  3,537
  4,075
  4,652
  5,269
  5,924
  6,616
  7,345
  8,110
  8,911
  9,748
  10,620
  11,528
  12,473
  13,456
  14,477
Revenue / Adjusted assets
  0.016
  0.020
  0.020
  0.019
  0.020
  0.022
  0.022
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
  0.021
Average production assets, $m
  27
  42
  63
  91
  129
  177
  238
  313
  402
  508
  631
  771
  930
  1,106
  1,301
  1,513
  1,743
  1,990
  2,254
  2,534
  2,830
  3,142
  3,469
  3,812
  4,170
  4,543
  4,932
  5,336
  5,756
  6,193
Working capital, $m
  -4
  -6
  -9
  -12
  -18
  -24
  -32
  -42
  -55
  -69
  -86
  -105
  -126
  -150
  -177
  -205
  -237
  -270
  -306
  -344
  -384
  -426
  -471
  -517
  -566
  -617
  -669
  -724
  -781
  -841
Total debt, $m
  3
  10
  19
  31
  47
  68
  95
  127
  166
  212
  266
  327
  396
  472
  557
  649
  749
  857
  971
  1,093
  1,222
  1,358
  1,500
  1,649
  1,804
  1,967
  2,136
  2,311
  2,494
  2,684
Total liabilities, $m
  12
  18
  27
  40
  56
  77
  104
  136
  175
  221
  274
  335
  404
  481
  566
  658
  758
  865
  980
  1,102
  1,231
  1,366
  1,509
  1,657
  1,813
  1,975
  2,144
  2,320
  2,503
  2,693
Total equity, $m
  52
  80
  120
  174
  246
  338
  453
  595
  766
  967
  1,201
  1,468
  1,769
  2,105
  2,475
  2,879
  3,317
  3,787
  4,289
  4,822
  5,386
  5,979
  6,602
  7,254
  7,935
  8,645
  9,384
  10,153
  10,953
  11,785
Total liabilities and equity, $m
  64
  98
  147
  214
  302
  415
  557
  731
  941
  1,188
  1,475
  1,803
  2,173
  2,586
  3,041
  3,537
  4,075
  4,652
  5,269
  5,924
  6,617
  7,345
  8,111
  8,911
  9,748
  10,620
  11,528
  12,473
  13,456
  14,478
Debt-to-equity ratio
  0.060
  0.120
  0.160
  0.180
  0.190
  0.200
  0.210
  0.210
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.220
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
  0.230
Adjusted equity ratio
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814
  0.814

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -34
  -51
  -74
  -106
  -149
  -203
  -272
  -356
  -458
  -578
  -713
  -872
  -1,051
  -1,251
  -1,472
  -1,712
  -1,973
  -2,253
  -2,552
  -2,870
  -3,205
  -3,559
  -3,930
  -4,319
  -4,725
  -5,148
  -5,589
  -6,047
  -6,524
  -7,020
Depreciation, amort., depletion, $m
  5
  5
  6
  7
  8
  10
  12
  14
  17
  21
  21
  26
  31
  37
  43
  50
  58
  66
  75
  84
  94
  105
  116
  127
  139
  151
  164
  178
  192
  206
Funds from operations, $m
  -29
  -46
  -68
  -100
  -141
  -194
  -260
  -342
  -441
  -557
  -692
  -846
  -1,020
  -1,214
  -1,428
  -1,662
  -1,915
  -2,187
  -2,477
  -2,785
  -3,111
  -3,454
  -3,815
  -4,192
  -4,586
  -4,996
  -5,424
  -5,869
  -6,332
  -6,813
Change in working capital, $m
  -1
  -2
  -3
  -4
  -5
  -7
  -8
  -10
  -12
  -14
  -17
  -19
  -22
  -24
  -26
  -29
  -31
  -34
  -36
  -38
  -40
  -42
  -44
  -47
  -49
  -51
  -53
  -55
  -57
  -59
Cash from operations, $m
  -28
  -44
  -66
  -96
  -136
  -187
  -252
  -332
  -429
  -543
  -675
  -827
  -999
  -1,190
  -1,402
  -1,633
  -1,884
  -2,153
  -2,441
  -2,747
  -3,071
  -3,412
  -3,770
  -4,145
  -4,537
  -4,946
  -5,372
  -5,814
  -6,275
  -6,754
Maintenance CAPEX, $m
  -1
  -1
  -1
  -2
  -3
  -4
  -6
  -8
  -10
  -13
  -17
  -21
  -26
  -31
  -37
  -43
  -50
  -58
  -66
  -75
  -84
  -94
  -105
  -116
  -127
  -139
  -151
  -164
  -178
  -192
New CAPEX, $m
  -7
  -15
  -21
  -28
  -38
  -48
  -61
  -75
  -90
  -106
  -123
  -140
  -158
  -176
  -195
  -212
  -230
  -247
  -264
  -280
  -296
  -312
  -327
  -343
  -358
  -373
  -389
  -404
  -420
  -437
Cash from investing activities, $m
  -8
  -16
  -22
  -30
  -41
  -52
  -67
  -83
  -100
  -119
  -140
  -161
  -184
  -207
  -232
  -255
  -280
  -305
  -330
  -355
  -380
  -406
  -432
  -459
  -485
  -512
  -540
  -568
  -598
  -629
Free cash flow, $m
  -36
  -59
  -88
  -126
  -176
  -240
  -319
  -415
  -529
  -662
  -815
  -989
  -1,183
  -1,398
  -1,633
  -1,889
  -2,164
  -2,458
  -2,771
  -3,102
  -3,452
  -3,818
  -4,202
  -4,603
  -5,022
  -5,458
  -5,912
  -6,383
  -6,873
  -7,383
Issuance/(repayment) of debt, $m
  3
  6
  9
  12
  16
  21
  26
  32
  39
  46
  53
  61
  69
  77
  85
  92
  100
  107
  115
  122
  129
  136
  142
  149
  156
  162
  169
  176
  183
  190
Issuance/(repurchase) of shares, $m
  48
  79
  114
  160
  220
  295
  388
  498
  628
  779
  947
  1,139
  1,353
  1,587
  1,842
  2,116
  2,410
  2,723
  3,054
  3,403
  3,769
  4,152
  4,553
  4,971
  5,406
  5,858
  6,328
  6,817
  7,324
  7,851
Cash from financing (excl. dividends), $m  
  51
  85
  123
  172
  236
  316
  414
  530
  667
  825
  1,000
  1,200
  1,422
  1,664
  1,927
  2,208
  2,510
  2,830
  3,169
  3,525
  3,898
  4,288
  4,695
  5,120
  5,562
  6,020
  6,497
  6,993
  7,507
  8,041
Total cash flow (excl. dividends), $m
  16
  26
  35
  46
  60
  77
  95
  116
  139
  163
  185
  212
  239
  266
  293
  320
  346
  372
  397
  422
  446
  470
  493
  516
  539
  562
  585
  609
  633
  658
Retained Cash Flow (-), $m
  -48
  -79
  -114
  -160
  -220
  -295
  -388
  -498
  -628
  -779
  -947
  -1,139
  -1,353
  -1,587
  -1,842
  -2,116
  -2,410
  -2,723
  -3,054
  -3,403
  -3,769
  -4,152
  -4,553
  -4,971
  -5,406
  -5,858
  -6,328
  -6,817
  -7,324
  -7,851
Prev. year cash balance distribution, $m
  132
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  100
  -53
  -79
  -114
  -160
  -219
  -292
  -382
  -490
  -616
  -762
  -928
  -1,114
  -1,321
  -1,549
  -1,796
  -2,064
  -2,351
  -2,657
  -2,981
  -3,323
  -3,683
  -4,060
  -4,455
  -4,866
  -5,296
  -5,743
  -6,207
  -6,691
  -7,193
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  96
  -48
  -69
  -94
  -124
  -159
  -198
  -239
  -281
  -323
  -362
  -396
  -424
  -444
  -455
  -457
  -449
  -433
  -409
  -379
  -344
  -306
  -266
  -227
  -189
  -155
  -123
  -96
  -73
  -54
Current shareholders' claim on cash, %
  60.2
  33.5
  19.2
  11.3
  6.8
  4.2
  2.6
  1.6
  1.1
  0.7
  0.5
  0.3
  0.2
  0.1
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

FINANCIAL RATIOS  of  Abeona Therapeutics (ABEO)

Valuation Ratios
P/E Ratio -14.7
Price to Sales 324
Price to Book 3.3
Price to Tangible Book
Price to Cash Flow -24.9
Price to Free Cash Flow -23.1
Growth Rates
Sales Growth Rate 0%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -23%
Ret/ On Assets - 3 Yr. Avg. -118%
Return On Total Capital -26.3%
Ret/ On T. Cap. - 3 Yr. Avg. 157.5%
Return On Equity -26.3%
Return On Equity - 3 Yr. Avg. 157.5%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 33.3%
EBITDA Margin -2100%
EBITDA Margin - 3 Yr. Avg. -2066.7%
Operating Margin -2400%
Oper. Margin - 3 Yr. Avg. -1533.3%
Pre-Tax Margin -2200%
Pre-Tax Margin - 3 Yr. Avg. -2133.3%
Net Profit Margin -2200%
Net Profit Margin - 3 Yr. Avg. -2133.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

ABEO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ABEO stock intrinsic value calculation we used $0.837 million for the last fiscal year's total revenue generated by Abeona Therapeutics. The default revenue input number comes from 0001 income statement of Abeona Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ABEO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ABEO is calculated based on our internal credit rating of Abeona Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Abeona Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ABEO stock the variable cost ratio is equal to 2800%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for ABEO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Abeona Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Abeona Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ABEO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ABEO are equal to 2037.1%.

Life of production assets of 53.6 years is the average useful life of capital assets used in Abeona Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ABEO is equal to -276.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $170.098 million for Abeona Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 40.287 million for Abeona Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Abeona Therapeutics at the current share price and the inputted number of shares is $0.3 billion.

RELATED COMPANIES Price Int.Val. Rating
AMAG AMAG Pharmaceu 18.00 51.08  str.buy
RGNX REGENXBIO 62.38 1.29  str.sell
ONCE Spark Therapeu 39.00 3.43  str.sell
VYGR Voyager Therap 12.18 1.30  str.sell
BLUE bluebird bio 122.78 7.95  str.sell
EDIT Editas Medicin 28.08 1.10  str.sell
ADVM Adverum Biotec 3.73 0.72  str.sell

COMPANY NEWS

▶ Abeona Therapeutics: 3Q Earnings Snapshot   [04:27PM  Associated Press]
▶ Abeona Announces Participation at Upcoming Conferences   [Sep-28-18 08:45AM  GlobeNewswire]
▶ Abeona Announces Participation at Upcoming Conferences   [Sep-04-18 08:45AM  GlobeNewswire]
▶ Abeona Therapeutics: 2Q Earnings Snapshot   [06:50PM  Associated Press]
▶ 9 Stocks Poised for Healthy Long-Term Gains   [Jun-04-18 02:30PM  Investopedia]
▶ Here's Why Abeona Therapeutics Stock Dropped 12% Today   [May-18-18 05:30PM  Motley Fool]
▶ Abeona Therapeutics: 1Q Earnings Snapshot   [May-11-18 08:25AM  Associated Press]
▶ Abeona Therapeutics Announces Upcoming Presentations   [May-08-18 08:15AM  GlobeNewswire]
▶ Kensho's genetic engineering index   [Apr-27-18 11:10AM  CNBC Videos]
▶ When Will Abeona Therapeutics Inc (NASDAQ:ABEO) Breakeven?   [Apr-12-18 09:27PM  Simply Wall St.]
▶ 7 Stocks for the Biotech Takeover Wave   [06:00AM  Investopedia]
▶ Why Abeona Therapeutics Jumped 14% on Wednesday   [Feb-07-18 07:01PM  Motley Fool]
▶ Traders Need to Adapt to a New Reality   [04:42PM  TheStreet.com]
▶ 7 Stocks Ready to Jump Another 30% in 2018   [Dec-19-17 01:37PM  InvestorPlace]
▶ Abeona Therapeutics reports 3Q loss   [Nov-15-17 08:31AM  Associated Press]
▶ Market Still Lacks Ability to Find Volatility   [Oct-20-17 01:19PM  TheStreet.com]
▶ Here's Why Abeona Therapeutics Inc. Stock Spiked Today   [Oct-11-17 12:11PM  Motley Fool]
▶ Andreas Halvorsen Scoops Up Abeona Therapeutics   [Oct-03-17 01:22PM  GuruFocus.com]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.